Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 13, Issue 12, 2009, Pages 1456-1466

  Borrell, S ^a   Gagneux, Sebastien ^a  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

Antibiotic; Evolution; Genotyping; Transmissibility; Virulence

Indexed keywords

RIFAMPICIN;

ANTIBIOTIC RESISTANCE; DRUG SENSITIVITY; MATHEMATICAL MODEL; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; REVIEW; VIRUS STRAIN; VIRUS TRANSMISSION;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MODELS, THEORETICAL; MOLECULAR EPIDEMIOLOGY; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 73649107809     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Jassal M, Bishai W R. Extensively drug-resistant tuberculosis. Lancet Infect Dis 2009; 9: 19-30.
2. World Health Organization. Anti-tuberculosis drug resistance in the world. Report no 4. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO, 2008.
3. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO/HTM/TB/2008.393. Geneva, Switzerland: WHO, 2008.
4. Dye C, Williams B G, Espinal M A, Raviglione M C. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 2002; 295: 2042-2046.
5. Cohen T, Sommers B, Murray M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis 2003; 3: 13-21.
6. Andersson D, Hughes D. Effects of antibiotic resistance on bacterial fitness, virulence and transmission. In: Baquero F, Nombela C, Cassell G H, Gutierrez-Fuentes J A, eds. Evolutionary biology of bacterial and fungal pathogens. Washington DC, USA: ASM Press, 2008: pp 307-318.
7. Ramaswamy S, Musser J M. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tubercle Lung Dis 1998; 79: 3-29.
8. Andersson D I, Levin B R. The biological cost of antibiotic resistance. Curr Opin Microbiol 1999; 2: 489-493.
9. Maisnier-Patin S, Andersson D I. Adaptation to the deleterious effects of antimicrobial drug resistance mutations by compensatory evolution. Res Microbiol 2004; 155: 360-369.
10. Middlebrook G, Cohn M L. Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli. Science 1953; 118: 297-299.
11. Mitchison D A. Tubercle bacilli resistant to isoniazid: virulence and response to treatment with isoniazid in guinea pigs. BMJ 1954: 128-130.
12. Ordway D J, Sonnenberg M G, Donahue S A, Belisle J T, Orme I M. Drug-resistant strains of Mycobacterium tuberculosis exhibit a range of virulence for mice. Infect Immun 1995; 63: 741-743.
13. Pym A S, Saint-Joanis B, Cole S T. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun 2002; 70: 4955-4960.
14. Cohen T, Becerra M C, Murray M B. Isoniazid resistance and the future of drug-resistant tuberculosis. Microb Drug Resist 2004; 10: 280-285.
15. Bottger E C, Springer B, Pletschette M, Sander P. Fitness of antibiotic-resistant microorganisms and compensatory mutations. Nat Med 1998; 4: 1343-1344.
16. Sander P, Springer B, Prammananan T, et al. Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob Agents Chemother 2002; 46: 1204-1211.
17. Billington O J, McHugh T D, Gillespie S H. Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999; 43: 1866-1869.
18. Gagneux S, Long C D, Small P M, Van T, Schoolnik G K, Bohannan B J. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006; 312: 1944-1946.
19. Mariam D H, Mengistu Y, Hoffner S E, Andersson D I. Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2004; 48: 1289-1294.
20. Bottger E C, Springer B. Tuberculosis: drug resistance, fitness and strategies for global control. Eur J Pediatr 2008; 167: 141-148.
21. Sherman D R, Mdluli K, Hickey M J, et al. Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 1996; 272: 1641-1643.
22. Gagneux S, Burgos M V, DeRiemer K, et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog 2006; 2: e61.
23. Cohen T, Dye C, Colijn C, Murray M. Mathematical models of the epidemiology and control of drug-resistant TB. Expert Rev Resp Med 2009 (in press).
24. Dye C, Espinal M A. Will tuberculosis become resistant to all antibiotics? Proc Biol Sci 2001; 268: 45-52.
25. Blower S M, Gerberding J L. Understanding, predicting and controlling the emergence of drug-resistant tuberculosis: a theoretical framework. J Mol Med 1998; 76: 624-636.
26. Blower S M, Chou T. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat Med 2004; 10: 1111-1116.
27. Cohen T, Murray M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med 2004; 10: 1117-1121.
28. Mathema B, Kurepina N E, Bifani P J, Kreiswirth B N. Molecular epidemiology of tuberculosis: current insights. Clin Microbiol Rev 2006; 19: 658-685.
29. Toungoussova O S, Sandven P, Mariandyshev A O, Nizovtseva N I, Bjune G, Caugant D A. Spread of drug-resistant Mycobacterium tuberculosis strains of the Beijing genotype in the Archangel Oblast, Russia. J Clin Microbiol 2002; 40: 1930-1937.
30. Garcia-Garcia M L, Ponce de Leon A, Jimenez-Corona M E, et al. Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico. Arch Intern Med 2000; 160: 630-636.
31. Burgos M, DeRiemer K, Small P M, Hopewell P C, Daley C L. Effect of drug resistance on the generation of secondary cases of tuberculosis. J Infect Dis 2003; 188: 1878-1884.
32. DeRiemer K, Garcia-Garcia L, Bobadilla-del-Valle M, et al. Does DOTS work in populations with drug-resistant tuberculosis? Lancet 2005; 365: 1239-1245.
33. van Soolingen D, Borgdorff M W, de Haas P E, et al. Molecular epidemiology of tuberculosis in the Netherlands: a nationwide study from 1993 through 1997. J Infect Dis 1999; 180: 726-736.
34. van Soolingen D, de Haas P E, van Doorn H R, Kuijper E, Rinder H, Borgdorff M W. Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance and successful transmission of Mycobacterium tuberculosis in The Netherlands. J Infect Dis 2000; 182: 1788-1790.
35. Fandinho F C, Kritski A L, Hofer C, et al. RFLP patterns and risk factors for recent tuberculosis transmission among hospitalized tuberculosis patients in Rio de Janeiro, Brazil. Trans R Soc Trop Med Hyg 2000; 94: 271-275.
36. Kruuner A, Hoffner S E, Sillastu H, et al. Spread of drug-resistant pulmonary tuberculosis in Estonia. J Clin Microbiol 2001; 39: 3339-3345.
37. Alland D, Kalkut G E, Moss A R, et al. Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994; 330: 1710-1716.
38. Godfrey-Faussett P, Sonnenberg P, Shearer S C, et al. Tuberculosis control and molecular epidemiology in a South African gold-mining community. Lancet 2000; 356: 1066-1071.
39. Snider D E Jr, Kelly G D, Cauthen G M, Thompson N J, Kilburn J O. Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir Dis 1985; 132: 125-132.
40. Teixeira L, Perkins M D, Johnson J L, et al. Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001; 5: 321-328.
41. van Doorn H R, de Haas P E, Kremer K, Vandenbroucke-Grauls C M, Borgdorff M W, van Soolingen D. Public health impact of isoniazid-resistant Mycobacterium tuberculosis strains with a mutation at amino-acid position 315 of katG: a decade of experience in The Netherlands. Clin Microbiol Infect 2006; 12: 769-775.
42. Cox H S, Sibilia K, Feuerriegel S, et al. Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis. N Engl J Med 2008; 359: 2398-2400.
43. Gandhi N R, Moll A, Sturm A W, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580.
44. Shafer R W, Small P M, Larkin C, et al. Temporal trends and transmission patterns during the emergence of multidrug-resistant tuberculosis in New York City: a molecular epidemiologic assessment. J Infect Dis 1995; 171: 170-176.
45. van Rie A, Warren R M, Beyers N, et al. Transmission of a multidrug-resistant Mycobacterium tuberculosis strain resembling 'strain W' among noninstitutionalized, human immunodeficiency virus-seronegative patients. J Infect Dis 1999; 180: 1608-1615.
46. Sofia M, Maniscalco M, Honore N, et al. Familial outbreak of disseminated multidrug-resistant tuberculosis and meningitis. Int J Tuberc Lung Dis 2001; 5: 551-558.
47. Quitugua T N, Seaworth B J, Weis S E, et al. Transmission of drug-resistant tuberculosis in Texas and Mexico. J Clin Microbiol 2002; 40: 2716-2724.
48. Palmero D, Ritacco V, Ambroggi M, et al. Multidrug-resistant tuberculosis in HIV-negative patients, Buenos Aires, Argentina. Emerg Infect Dis 2003; 9: 965-969.
49. Samper S, Iglesias M J, Rabanaque M J, et al. Systematic molecular characterization of multidrug-resistant Mycobacterium tuberculosis complex isolates from Spain. J Clin Microbiol 2005; 43: 1220-1227.
50. Mardassi H, Namouchi A, Haltiti R, et al. Tuberculosis due to resistant Haarlem strain, Tunisia. Emerg Infect Dis 2005; 11: 957-961.
51. Oeltmann J E, Varma J K, Ortega L, et al. Multidrug-resistant tuberculosis outbreak among US-bound Hmong refugees, Thailand, 2005. Emerg Infect Dis 2008; 14: 1715-1721.
52. Kodmon C, Niemann S, Lukacs J, Sor E, David S, Somoskovi A. Molecular epidemiology of drug-resistant tuberculosis in Hungary. J Clin Microbiol 2006; 44: 4258-4261.
53. Umubyeyi A N, Shamputa I C, Rigouts L, et al. Molecular investigation of recurrent tuberculosis in patients from Rwanda. Int J Tuberc Lung Dis 2007; 11: 860-867.
54. Vazquez-Gallardo R, Anibarro L, Fernandez-Villar A, et al. Multidrug-resistant tuberculosis in a low-incidence region shows a high rate of transmission. Int J Tuberc Lung Dis 2007; 11: 429-435.
55. Masjedi M R, Farnia P, Sorooch S, et al. Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran. Clin Infect Dis 2006; 43: 841-847.
56. Mlambo C K, Warren R M, Poswa X, Victor T C, Duse A G, Marais E. Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa. Int J Tuberc Lung Dis 2008; 12: 99-104.
57. Luo N, Pereira S, Sahin O, et al. Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure. Proc Natl Acad Sci USA 2005; 102: 541-546.
58. Gagneux S, Small P M. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis 2007; 7: 328-337.
59. Nicol M P, Wilkinson R J. The clinical consequences of strain diversity in Mycobacterium tuberculosis. Trans R Soc Trop Med Hyg 2008; 102: 955-965.
60. Gagneux S, Deriemer K, Van T, et al. Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2006; 103: 2869-2873.
61. Basu S, Orenstein E, Galvani A P. The theoretical influence of immunity between strain groups on the progression of drug-resistant tuberculosis epidemics. J Infect Dis 2008; 198: 1502-1513.
62. Pfyffer G E, Strassle A, van Gorkum T, et al. Multidrug-resistant tuberculosis in prison inmates, Azerbaijan. Emerg Infect Dis 2001; 7: 855-861.
63. Park Y K, Shin S, Ryu S, et al. Comparison of drug resistance genotypes between Beijing and non-Beijing family strains of Mycobacterium tuberculosis in Korea. J Microbiol Methods 2005; 63: 165-172.
64. Kovalev S Y, Kamaev E Y, Kravchenko M A, Kurepina N E, Skorniakov S N. Genetic analysis of Mycobacterium tuberculosis strains isolated in Ural region, Russian Federation, by MIRU-VNTR genotyping. Int J Tuberc Lung Dis 2005; 9: 746-752.
65. Cox H S, Kubica T, Doshetov D, Kebede Y, Rüsch-Gerdes S, Niemann S. The Beijing genotype and drug resistant tuberculosis in the Aral Sea region of Central Asia. Respir Res 2005; 6: 134.
66. Drobniewski F, Balabanova Y, Nikolayevsky V, et al. Drug-resistant tuberculosis, clinical virulence and the dominance of the Beijing strain family in Russia. JAMA 2005; 293: 2726-2731.
67. European Concerted Action on New Generation Genetic Markers and Techniques for the Epidemiology and Control of Tuberculosis. Beijing/W genotype Mycobacterium tuberculosis and drug resistance. Emerg Infect Dis 2006; 12: 736-743.
68. Nikolayevskyy V V, Brown T J, Bazhora Y I, Asmolov A A, Balabanova Y M, Drobniewski F A. Molecular epidemiology and prevalence of mutations conferring rifampicin and isoniazid resistance in Mycobacterium tuberculosis strains from the southern Ukraine. Clin Microbiol Infect 2007; 13: 129-138.
69. Sun Y J, Lee A S, Wong S Y, et al. Genotype and phenotype relationships and transmission analysis of drug-resistant tuberculosis in Singapore. Int J Tuberc Lung Dis 2007; 11: 436-442.
70. Mokrousov I, Otten T, Zozio T, et al. At Baltic crossroads: a molecular snapshot of Mycobacterium tuberculosis population diversity in Kaliningrad, Russia. FEMS Immunol Med Microbiol 2009; 55: 13-22.
71. Phyu S, Stavrum R, Lwin T, Svendsen O S, Ti T, Grewal H M. Predominance of Mycobacterium tuberculosis EAI and Beijing lineages in Yangon, Myanmar. J Clin Microbiol 2009; 47: 335-344.
72. Chopra I, O'Neill A J, Miller K. The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist Updat 2003; 6: 137-145.
73. Dos Vultos T, Mestre O, Rauzier J, et al. Evolution and diversity of clonal bacteria: the paradigm of Mycobacterium tuberculosis. PLoS ONE 2008; 3: e1538.
74. Werngren J, Hoffner S E. Drug-susceptible Mycobacterium tuberculosis Beijing genotype does not develop mutation-conferred resistance to rifampin at an elevated rate. J Clin Microbiol 2003; 41: 1520-1524.
75. Hershberg R, Lipatov M, Small P M, et al. High functional diversity in Mycobacterium tuberculosis driven by genetic drift and human demography. PLoS Biology 2008; 6: e311.
76. Toungoussova O S, Caugant D A, Sandven P, Mariandyshev A O, Bjune G. Impact of drug resistance on fitness of Mycobacterium tuberculosis strains of the W-Beijing genotype. FEMS Immunol Med Microbiol 2004; 42: 281-290.
77. Sandgren A, Strong M, Muthukrishnan P, Weiner B K, Church G M, Murray M B. Tuberculosis drug resistance mutation database. PLoS Med 2009; 6: e2.
78. Dhar N, McKinney J D. Microbial phenotypic heterogeneity and antibiotic tolerance. Curr Opin Microbiol 2007; 10: 30-38.
79. Dye C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol 2009; 7: 81-87.